Affymetrix And EBioscience Amend Definitive Merger Agreement

Affymetrix, Inc., (NASDAQ:AFFX) and eBioscience, Inc., a privately-held San Diego, CA-based company with an industry-leading position in flow cytometry and immunoassay reagents for immunology and oncology research and diagnostics, today announced they have amended their existing definitive agreement dated November 29, 2011 under which Affymetrix will acquire eBioscience. Under the terms of the amended agreement, Affymetrix will acquire eBioscience for $315 million in cash subject to usual adjustments. The transaction remains subject to customary closing conditions and is now expected to close late in the quarter ending June 30, 2012.

As previously announced, Affymetrix expects the acquisition of eBioscience to:
  • Create significant new commercial opportunities in the key post-genomic applications of immunology, oncology, cell biology, stem cell biology, and diagnostics
  • Diversify the Company's revenues and complement its genomics franchise
  • Augment the Company's growing business in diagnostics
  • Expand the Company's product portfolio to include multicolor flow cytometry reagents and a broad spectrum of reagents for the analysis of cytokines, growth factors and other soluble proteins
  • Enhance the operational and new product opportunities for Panomics RNA and protein analysis products
  • Leverage the commercial capabilities of both companies to generate new opportunities for growth

"The feedback from our customers, shareholders and partners has been consistently positive since we announced our original agreement with eBioscience last November," said Dr. Frank Witney, president and chief executive officer of Affymetrix. "By amending the transaction, we are now able to realize the benefits of combining with eBioscience with significantly less senior secured debt than under the original agreement. With eBioscience, Affymetrix will expand its addressable markets by adding an industry-leading portfolio of cell-based and immunoassays. These new products are a critical part of our customers' workflow in our key target markets of translational medicine, oncology, and immunology. We believe that these markets represent a nearly $3 billion annual opportunity, which will put Affymetrix on a solid path to sustained growth and profitability. We look forward to welcoming the eBioscience team to the Affymetrix family."

If you liked this article you might like

Thermo Fisher Adds Electron Microscopy Specialist FEI in $4.2B Deal

Affymetrix (AFFX) Stock Retreats After Origin Withdraws Takeover Bid

Today's Pre-Market Mover With Heavy Volume: Affymetrix (AFFX)

Affymetrix (AFFX) Stock Drops After Rejecting Origin Technologies Takeover Bid

Affymetrix (AFFX) Stock Lower, to Engage in Bid Talks with Origin Technologies